Patents by Inventor Orit Foord

Orit Foord has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD324 monoclonal antibodies and uses thereof
    Patent number: 9534058
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: January 3, 2017
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Robert A. Stull, Monette Aujay, Orit Foord, Alex Bankovich, Johannes Hampl, Scott J. Dylla, David Liu
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9486537
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 8, 2016
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9480757
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 1, 2016
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9481727
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 1, 2016
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Antibodies Directed To GPNMB And Uses Thereof
    Publication number: 20160311919
    Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
    Type: Application
    Filed: February 25, 2016
    Publication date: October 27, 2016
    Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael E. Jeffers, William J. LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
  • NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE
    Publication number: 20160289332
    Abstract: Provided herein are novel anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Application
    Filed: November 5, 2014
    Publication date: October 6, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Marianne SANTAGUIDA, Monette AUJAY, Laura SAUNDERS, David LIU, Orit FOORD, Robert A. STULL, Paul Anthony ESCARPE
  • Modulators and methods of use
    Patent number: 9458231
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: October 4, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Scott J. Dylla, Orit Foord, Robert A. Stull, Wade C. Anderson, Saiyou Ohshima
  • NOVEL MODULATORS AND METHODS OF USE
    Publication number: 20160272723
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
    Type: Application
    Filed: March 30, 2016
    Publication date: September 22, 2016
    Applicant: STEMCENTRX, INC.
    Inventors: ORIT FOORD, SCOTT J. DYLLA, ROBERT A. STULL, ALEX BANKOVICH, ALEXANDRA LEIDA LIANA LAZETIC, JEFFREY BERNSTEIN
  • NOVEL MODULATORS AND METHODS OF USE
    Publication number: 20160264653
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.
    Type: Application
    Filed: March 17, 2016
    Publication date: September 15, 2016
    Applicant: STEMCENTRX, INC.
    Inventors: JOHANNES HAMPL, SCOTT J. DYLLA, ORIT FOORD, ROBERT A. STULL
  • NOVEL MODULATORS AND METHODS OF USE
    Publication number: 20160257745
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.
    Type: Application
    Filed: March 17, 2016
    Publication date: September 8, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: JOHANNES HAMPL, SCOTT J. DYLLA, ORIT FOORD, ROBERT A. STULL
  • Anti-DLL3 antibody drug conjugates
    Publication number: 20160251431
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: April 21, 2016
    Publication date: September 1, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. STULL, Laura SAUNDERS, Scott J. DYLLA, Orit FOORD, David LIU, Michael TORGOV, Hui SHAO
  • Anti-DLL3 antibody drug conjugates
    Publication number: 20160250348
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: April 21, 2016
    Publication date: September 1, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. STULL, Laura SAUNDERS, Scott J. DYLLA, Orit FOORD, David LIU, Michael TORGOV, Hui SHAO
  • Anti-DLL3 antibody drug conjugates
    Publication number: 20160228571
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 11, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. STULL, Laura SAUNDERS, Scott J. DYLLA, Orit FOORD, David LIU, Michael TORGOV, Hui SHAO
  • PTK7 modulators and methods of use
    Patent number: 9409995
    Abstract: PTK modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyper-proliferative disorders are provided.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: August 9, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Orit Foord, Scott J. Dylla, Robert A. Stull, Alex Bankovich, Alexandra Leida Liana Lazetic, Jeffrey Bernstein
  • ENGINEERED GAMMA DELTA T-CELLS
    Publication number: 20160175358
    Abstract: The present invention relates to engineered ?? T-cell(s) and methods for using the same as a therapeutic with a potent and selective ability to target an antigen of choice. Engineered ?? T-cells of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also disclosed are methods for expanding engineered and non-engineered ?? T-cell(s) populations to therapeutically useful quantities. An engineered ?? T-cell of the disclosure can be a universal donor, and can be administered to a subject with any MHC haplotype.
    Type: Application
    Filed: November 17, 2015
    Publication date: June 23, 2016
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida
  • KITS CONTAINING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20160158379
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: January 25, 2016
    Publication date: June 9, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Methods of making DLL3 antibody drug conjugates
    Patent number: 9358304
    Abstract: Novel modulatators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: June 7, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • METHODS OF DELIVERING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20160151513
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: January 25, 2016
    Publication date: June 2, 2016
    Applicant: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DLL3 antibodies
    Patent number: 9353182
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: May 31, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Kits containing DLL3 antibody drug conjugates
    Patent number: 9352051
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: May 31, 2016
    Assignee: Stemcentrx, Inc.
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao